Language selection

Search

Patent 1043775 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1043775
(21) Application Number: 1043775
(54) English Title: PROCESS FOR RECOVERING GLUCAGON
(54) French Title: RECUPERATION DE GLUCAGON
Status: Term Expired - Post Grant Beyond Limit
Bibliographic Data
Abstracts

English Abstract


ABSTRACT OF DISCLOSURE
The invention provides a process for the recovery
of glucagon by
A. isolating glucagon-containing protein from
insulin process alkaline crystallization super-
natant;
B. separating the glucagon from other proteins;
and
C. purifying the glucagon obtained from step B.


Claims

Note: Claims are shown in the official language in which they were submitted.


The embodiment of the invention for which an ex-
clusive property or privilege is claimed are defined as
follows:
1. A process for the recovery of glucagon, which
comprises:
A. isolating glucagon-containing protein from
insulin process alkaline crystallization
supernatant;
B. separating the glucagon from other proteins; and
C. purifying the glucagon obtained from step B.
2. The process of claim 1, wherein step A is
accomplished by means of isoelectric precipitation at a pH
from about 4.2 to about 6.6.
3. The process of claim 2, wherein said isoelectric
precipitation is carried out in the presence of up to about
20 volume percent of a saturated aliphatic monoalcohol having
fewer than about six carbon atoms.
4. The process of claim 3, wherein said monoalcohol
is ethyl alcohol.
5. The process of claim 1, wherein step A is
accomplished by means of ion-exchange chromatography.
6. The process of claim 1, wherein step A is
accomplished by means of isoelectric precipitation and ion-
exchange chromatography in any order.
7. The process of claim 1, wherein step A is
accomplished by means of isoelectric precipitation, followed
by a hyperglycemic factor fractionation.
8. The process of claim 1, wherein step B is
accomplished by means of glucagon fibril formation.
-24-

9. The process of claim 8, wherein said fibril
formation is carried out at a pH in the range of from about
1.5 to about 2.7.
10. The process of claim 8, wherein said fibril
formation is carried out in the presence of an inorganic salt.
11. The process of claim 10, wherein said salt is
ammonium sulfate.
12. The process of claim 8, wherein ammonium
sulfate is present at a concentration of from about 0.01 to
about 0.05 M.
13. The process of claim 1, wherein step C is
accomplished by means of crystallization.
14. The process of claim 13, wherein said
crystallization is carried out at a pH in the range of
from about 4.5 to about 8.5.
15. The process of claim 13, wherein said crystal-
lization is carried out with a glucagon concentration of
from about 2 to about 10 mg. glucagon per ml. of solution.
16. The process of claim 14, wherein two successive
crystallizations are carried out.
17. The process of claim 14, wherein a first
crystallization is carried out at a pH in the range of from
about 4.5 to about 5.5, and a second crystallization is
carried out at a pH in the range of from about 7.0 to
about 8.5.
18. The process of claim 1, wherein step B is
accomplished by means of glucagon fibril formation and step
C is accomplished by means of crystallization.
-25-

19. The process of claim 18, wherein step A is
accomplished by means of isoelectric precipitation.
20. The process of claim 18, wherein step A is
accomplished by means of ion-exchange chromatography.
21. The process of claim 18, wherein step A is
accomplished by means of isoelectric precipitation and ion-
exchange chromatography in any order.
22. A process for the recovery of glucagon which
comprises:
A. isolating glucagon-containing protein from
insulin process alkaline crystallization super-
natant by isoelectric precipitation at pH 5.2
followed by hyperglycemic factor fractionation
at pH 7.5;
B. separating the glucagon from other proteins
by forming glucagon fibrils in hydrochloric
acid-phenol water in the presence of ethylene-
diamine-tetraacetic acid and ammonium sulfate;
and
C. purifying the glucagon obtained from step B by
crystallization at pH 5Ø
-26-

Description

Note: Descriptions are shown in the official language in which they were submitted.


~ ~3t7~
The invention relates to a process for the recovery
; of glucagon from insulin process alkaline crystallization
supernatant.
The invention provides a process for the recovery
of glucagon by
. isolating glucagon-containing protein from
insulin process alkaline crystallization super-
natant;
B. separating the glucagon from other proteins;
1~ and
C. purifying the glucagon obtained from step B.
Shortly after the ~iscovery of insulin in 1921 by
Banting and Best, several researchers [Murlin et al., J. Biol.
Chem., 56, 252 (1923) and Ximball and Murlin, J.
Biol. Chem., 58, 337 (1924)] noted that a hyperglycemic
response was obtained with certain pancreatic extracts of
insulin. The factor responsible for the hyperglycemic - ;
response was named glucagon.
At the present time, the most important use of
glucagon is in the treatment of insulin-induced hyperglycemia.
As the world diabetic population grows, the demand for
glucagon must increase. Additionally, the use of glucagon
in cardiac disorders currently is being explored.
Consequently, these two applications are placing increasing
demands on the production of glucagon, demands which are
met best by improving the yield of glucagon from natural
~` sources.
The first preparation of crystalline glucagon
was reported in 1953 [Staub, et al., Science, 117, 628 (19533;
see also, Staub, et al., J. Biol. Chem~, 214, 61g ~1955)].
X-3572 -2- ~
~' ~ ' , .
,

3~,3
The starting material was an amorphous fraction obtained
during the commercial manufacture o~ insulin which
involved an acid-alcohol extraction of pancreas tissue,
concentration of the extract, precipitation with sodium
chloride, isoelectric precipitation, several alcohol
fractionations, decolorization, crystallization with ~inc
from acetate buffer, washing to remove the amorphous
fraction, and drying the zinc insulin thus obtained. The
amorphous fraction contained about four weight percent
glucagon and about seven weight percent insulin. Usually,
the yield of amorphous material was in the range of from
about five to about ten mg. per pound of pancreas.
The glucagon preparation in turn involved, optionally,
fractionation at pH 6.7, acetone fractionation, fractional
precipitation at pH 4.3, two fractional precipitations at
pH 2.5, and two crystallizations from urea-glycine buffer
at pH 8.6. The yield of crystalline glucagon was about
20 weight percent o~ the glucagon contained in dry
amorphous material, which corresponded to a yield of
from about 0.04 to about 0.08 mg. of glucagon per pound of
pancreas.
The introduction of an intermediate crystallization
of zinc insulin from citrate buffer, as taught by U.S.
Patent 2,626,228, resulted in an overall reduction in the
total number of steps required in the insulin manufactur-
ing process using beef pancreas. While approximately the
same amount of amorphous fraction was obtained during the
washing step as in the older process, glucagon content of
the amorphous fraction had decreased to only about 0.2
weight percent. It was discovered that the glucagon was
X-3572 ~3~
: . . -. .................... , . : . ...... ,:; - -
.. . . - ~, -.; . . . :,

7~
retained in the citrate buffer during the intermediate
crystallization- Recovery of glucagon from the citrate
buffer required precipitation with excess zinc, followed
by a salt precipitation and two precipitations at pH 5.1
and 5.6, respectively, to remove the zinc. The yield of
crude glucagon from citrate buffer corresponded to about
0.8-0.9 mg. per pound of pancreas, from which source
the yield of purified glucagon corresponded to about 0.1-
0.3 mg. per pound of pancreas. The use of zinc as a
precipitating agent made complete removal of zinc difficult
and increased the amount of insulin carried over into
the final puxified glucagon.
Studies on pancreas extractions have shown that the
various acid-alcohol extracts usually employed in insulin
manufacturing processes contain 4-6 mg. of glucagon per
pound of pancreas. After concentrating and defatting the
extracts, glucagon content decreases to 1.5-2.0 mg. per
pound. However, as-discussed hereinabove, only about 25 to
50 weight percent of this amount is available for purifica-
tion, depending upon the starting material.
The drawing is a flow dia~ram of a preferred em-
bodiment of the present invention. The drawing also il-
lustrates the relationship of the process of the present
invention to the alkaline crystallization step of the
~ insulin process.
; The source of glucagon for the process is the
supernatant from the insulin process alkaline crystallization
step, disclosed in U.S. Paten~; 3,719,65S. This supernatant is an
aqueous solution showing a pH from 7.2 - 10.0 and a cation
concentration of 0.2 - 1~0 molar and has dissolved therein
X-3572 _4
~ ~ .

~"~L7t 3 ~ 7 ~ ~
protein which is about 1-10 percent insulin and about 0.2-
1.5 percent glucagon, depending upon the source of pancreas
employed in the insulin process. For example, with beef
pancreas this alkaline crystallization supernatant
protein usually contains about 5 - 10 percent insulin ~-~
and 1.0 - 1.5 percent glucagon; with pork pancreas, the
supernatant protein usually contains about 1-2 percent
insulin and about 0.2 - 0.3 percent glucagon. It should be
noted, however, that the actual yields of glucagon on a
batch-to-batch basis can vary over a wide range because
of the susceptibility of glucagon to enzymatic degradation.
Separation of glucagon-containing protein from
the alkaline crystallization supernatant comprises the
first step of the process. In general, such a separation
can be accomplished by any known method. For example, the pH
of the supernatant can be adjusted to about 3.0 and 20 percent,
weight per volume, of sodium chloride added to precipitate
glucagon and other proteins. Alternatively, precipitation can
be accomplished by the addition of excess zinc chloride
at a pH o~ about 6Ø A third procedure involves the
use of isoelectric precipitation. Yet another procedure
involves the use of ion-exchange chromatography. ;~
The second step of the process comprises separating
glucagon from other proteins. This separation in general can `
be accomplished by any known method, such as gel filtration,
ion-exchange chromatography, isoelectric focusing, and glu-
cagon fibril formation, of which methods glucagon fibril for-
mation is preferred.
The third and final step of the process comprises
purifying the glucagon obtained from step two. In general,
X-3572 -5-

3~r~
such purification can be accomplished by any of the methods
known to those skilled in the art, such as crystallization,
ion-exchange chromatography, and the like. Crystallization is
the preferred method.
The use of isoelectric precipitation or ion-exchange
chromatography, or some combination thereof, is preferred
for separating glucagon-containing protein from alkaline
crystallization supernatant. In general, isoelectric
precipitation requires that the supernatant pH be in the
range of from about 4.2 to about 6.6. The preferred pH
range is from about 4.6 to about 5.2, while the most
preferred range is from about 4.7 to about 5Ø
, Because the alkaline crystallization supernatant
is at a pH of from about 7.2 to about 10, it is necessary to
acidify the supernatant to the desired pH. Such acidifica-
tion normally can be accomplished simply by adding a
dilute solution of an inorganic or organic acid which will
not degrade or interact with glucagon. Examples of suit-
able acids include hydrochloric acid, phosphoric acid,
~' ~ 20 formic acid, acetic acid, propionic acid, and the like.
Hydrochloric acid is preferred.
Optionally, and preferably, up to about 20 volume
pexcent of an alcohol can be added to reduce the solubility
, - of the glucagon~containing protein in the alkaline
?
crystallization supernatant. By the term "alcohol" is
meant a saturated aliphatic monoalcohol having fewer
than about six carbon atoms. Preferably, the alcohol will
have fewer than about four carbon atoms, such as methyl
alcohol, ethyl alcohol, propyl alcohol, and isopropyl
alcohol. The most preferred alcohol is ethyl alcohol.
; X-3572 ~_
- . . .
: .
.~. . . .. . . ~
. .. . .
.. . .

7 ~
When employed, the alcohol normally is added to the super-
natant before acidification.
Upon acidifying the supernatant to the desired pH,
precipitation of the desired glucagon-containing protein
; begins quickly, usually within minutes. To ensure complete
precipitation, the solution is allowed to stand, usually
at a temperature no higher than ambient temperature.
Preferably, the solution is chilled to a temperature of
from about 3C. to about lO~C. Although precipitation
generally is complete after about 24 hours, the mixture can
be allowed to stand indefinitely without deleterious effects.
When precipitation is complete, the precipitate,
referred to hereinafter as isoelectric precipitate, is
isolated by any convenient known method, such as centrifugation
or filtration; filtration usually is preferred. The isoelectric
precipitate thus obtained need not be-washed or dried,
although such procedures can be employed if desired.
Another procedure well-suited to the separation of
glucagon-containing protein from alkaline crystallization
supernatant is ion-exchange chromatography. Of the known
ion-exchange procedures, the process of U.S. Patent 3,715,345 is
; especially effective and is preferred. Briefly, the process
of ion-exchange chromatography consists of passing the glu-
cagon-containing solution over an alkali metal form of a sul-
fonated macroreticular styrene-divinylbenzene copolymer resin
at pH 7-8. The glucagon is adsorbed onto the resin. The ; ;
glucagon is then eluted with a dilute base such as 0.1 N
ammonium hydroxide~ The glucagon containing eluant is -~
adjusted to pH 2.5 and then the glucagon is precipitated by a
standard "salt precipitation" method. The resulting glucagon- ;~
X-3~72 -7-
'-.
7'
:,,, . , . ~ ' , . ~
., . : ~ . .
~, . . . ~

r~5
containing precipitate has been substantially separated from
insulin proteins but the precipitate still contains other
non-glucagon materials.
Subjecting alkaline crystallization supernatant
to the process of U.S. Patent 3,715,345 results in an insulin-
containing eluant and a glucagon-containing salt cake. The
insulin-containing eluant, if desired, can be returned to the
insulin process. The glucagon-containing salt cake is re-
dissolved for further processing; for convenience, the solution ~-
pH and protein concentration in general are made approximatelyequivalent to that of alkaline crystallization supernatant.
It frequently may be advantageous in carrying out
the first step of the process i.e., separation of glucagon-
containing protein from alkaline crystallization supernatant,
to employ isoelectric precipitation and ion-exhange chroma-
tography in sequence. For example~ a]kaline crystalline super- -
natant can be subjected to the process of ion-exchange chroma-
tography. The~glucagon-containing salt cake thus obtained is
.
re-dissolved and subjected to isoelectric precipitation as
described hereinbefore. Alternatively, the alkaline crystal-
lization supernatant is subjected to isoelectric precipitation;
the precipitate obtained therefrom can be dissolved in a
slightly alkaline aqueous medium and subjected to the process
of ion-exchange chromatography. In each case, the insulin-
containing eluant from the ion-exchange chromatography can be
returned, if desired, to the insulin process. -
As stated hereinbeore, the preferred method for
the separation of glucagon from other protein is glucagon
fibril formation. In general, the formation of glucagon
fibrils is carried out in acidic, aqueous solution. Normally,
X-3572 -~_
~ . .
,,

7~7~
the glucagon-containing protein is dissolved in an acidic,
aqueous medium having a pH below about 2.7. While the pH
generally can range from about 1.5 to about 2.7, the
preferred pH range is from about 2.0 to about 2.5. While
any of the acids suitable for use in acidifying alkaline
crystallization supernatant prior to an isoelectric
precipitation can be employed, hydrochloric acid again is
preferred. With hydrochloric acid, however, a preservative,
such as phenol, should be employed, usually at a concentra-
tion of about 0.2 percent, weight per volume. Typically,the glucagon-containing protein is dissolved in 0.01 N hydro-
chloric acid containing 0.2 percent phenol, weight per
volume.
The concentration of glucagon-containing protein in
solution in general can range from about 2.5 to about 30 ~`
mg./ml. The preferred range is from about 5 to about
20 mg./ml., and the most preferred range is from about 5
to about 10 mg./ml~
Optionally, a water-soluble inorganic salt can be
added to the acidic glucagon-containing protein solution
to initiate fibril formation. The term "water-soluble" is
meant to include inorganic salts which are soluble in water
at the concentrations employed as described hereinafter.
Because the inorganic salt is believed primarily to have
a salting-out effect relative to the initiation of fibril
formation, the choice of inorganic salt is not critical.
Practically, however, the use of radioactive, toxic, or
colored salts, or salts which are oxidizing agents, reducing
agents, or strongly acidic or basic, is not desired for
obvious reasons. Thus, the suitable inorganic salts
~-3572 _9_
;
, : . ~ - ~ . : ,

7~7~
generally include the water-soluble ammonium salts, the
water-soluble salts of alkali metals up to and including
period 6 of the periodic table of the elements (Robert C.
Weast, Ed.-in-Chief, "Handbook of Chemistry and Physi~s,"
53rd Edition, The Chemical Rubber Co., Cleveland, Ohio,
1972, p. B3), and the water-soluble salts of the alkaline
earth metals up to and including period 6 of the periodic
table of the elements. Examples of such salts include,
among others, ammonium bromide, ammonium chloride,
ammonium fluoride, ammonium iodide, ammonium magnesium
sulfate, ammonium manganese sulfate, ammonium nitrate,
ammonium sulfate, lithium bromide, lithium chloride,
lithium fluosilicate, lithium fluosulfonate, lithium
iodide, lithium molybdate, lithium nitrate, lithium
potassium sulfate, sodium ammonium phosphate, sodium
ammonium sulfate, sodium bromide, sodium chloride, sodium
iodide, sodium hexafluorophosphate, sodium fluosulfonate,
sodium magnesium sulfate, sodium nitrate, sodium hex~-
metaphosphate, sodium dihydrogen orthophosphate, s~dium
monohydrogen orthophosphate, sodium sulfate, sodium hydrogen ~:
sulfate, potassium bromide, potassium calcium chloride,
potassium chloride, potassium fluoride, potassium iodide,
potassium magnesium chloride sulfate, potassium ma~nesium
sulfate, potassium magnesium chloride, potassium molybdate, ..
potassium orthophosphate, potassium sodium sulfate,
rubidium bromide, rubidium chloride, rubidium fluoride, ;
rubidium iodide, rubidium nitrate, cesium bromide, cesium
chloride, cesium fluoride, cesium iodide, cesium nitrate,
cesium sulfate, beryllium bromide, beryllium chloride, beryl- -
lium fluoride, beryllium nitrate, beryllium orthophosphate,
X-3572 -10~
.

- \
magnesium bromide, magneslum chloride, magnesium iodide,
magnesium nitrate, magnesium silicofluoride, calcium bromide,
calcium chloride, calcium iodide, calcium nitrate, strontium
bromide, strontium chloride, strontium iodide, barium
bromide, barium iodide, water-soluble hydrates thereof,
and the like. Ammonium salts are preferred, with
ammonium sulfate being most preferred. The suitable
inorganic salts in general can be employed in concentrations
up to about 0.5 M. Preferably, such salts will be present
10in concentrations of from about 0.01 to about 0.05 M.
The temperature range in which glucagon fibril
formation occurs normally is from about 20 to about 30C.
The preferred temperature range is from about 24 to about
26 C. The most preferred temperature is 25C.
Fibril formation, which is aided by agitation,
usually begins within about 3 to 4 hours from the time
preparation of the acidic, aqueous glucagon solution has
been completed, and is complete in about 48 hours. Formation
times in excess of about 48 hours usually are not necessary. ~ -
- When fibril formation is complete, the glucagon
- ; -fibril~ oan be collected by any known method, such as
filtratio~ or centrifugation, the later method being preferred.
If desired, the glucagon fibrils can be washed by ~uspending ; ~-
the fibrils in aqueous acid medium which may or may not
.
contain inorganic salt. The temperature of the wash medium
can be in the range of from about 20 to about 30C., with
~ 25C. being preferred. The fibrils then are collected
g as be~e and kept cold, usually at a temperature below
$
-: - ab~.u~ lOPC-~, if the next step is not carried out immediately.
X-3572 -11-
.. ~ .
: . -' .
. . .
.... ~.. - :: . . : ~
... : .,, . . ., . :

,7q5 ~ :
If desired, a chelating agent such as ethylene-
diaminetetraacetic acid can be included in the fibril-
forming medium. The concentration of chelating agent
normally will be less than about 0.01 M., the preferred
concentration being 0.004 M. However, the use of a
chelating agent is not preferred unless zinc or other
divalent metal ions are known to be present.
As stated hereinbefore, crystallization is the
preferred method for purifying the glucagon obtained in
the second step. In general, crystallization of glucagon
is carried out by dissolving the glucagon in an alkaline ~ -
aqueous medium and acidifying to a slightly alkaline or
acidic pH to initiate crystallization; i.e., to a pH in
the range of from about 4.5 to about 8.5.
Dissolution of the glucagon can be accomplished --
by either of two ways. First, the glucagon can be dissolved
directly in an alkaline aqueous medium. Or, the glucagon
can be suspended in distilled water and the pH adjusted
by the addition of aqueous base. Suitable bases in
~ 20 general are the alkali metal and ammonium hydroxides, of
; which potassium hydroxide is preferred.
In general, the resulting glucagon solution can have
a pH in the range of from about 9.0 to about 11.5, with
the preferred range being from about 9.5 to about 10.5.
;~ The concentration of glucagon in the alkaline solu-
tion should be within the range of from about 2 to about 10
mg./ml. The preferred concentration range is from about 4 to
about 8 mg./ml., with the most preferred concentrat~on boeing
about 5 mg./ml.
,
X-3572 -12-
~, ... : ;
.
'~' : ' ' ' ' - ., : .' ,

`7~
Because acidification frequently results in the immediate
precipitation of a small amount of non-glucagon protein, the
following acidification procedure, while not essential, is preferred.
The alkaline glucon solution is heated to a temperature
of from about 55 to about 65C. The solution then is acidified
to a pH of from about 4 to about 6 with 10 percent phosphoric acid.
While any of the acids suitable for use in previous steps can be
employed, the use of phosphoric acid is preferred. The resulting
solution then is filtered while still at the initial elevated
temperature. In general, the filtration step is optional and
frequently can be omitted when the amount of precipitate resulting
from the acidification is minimal. Furthermore, procedures other
than filtration, such as centrifugation, can be employed if desired.
If the glucagon solution is discolored, decolorizing
carbon can be added either before or after acidification,
preferably before.
After acidification (and filtrat:ion, if employed), the
glucagon solution is allowed to stand at a temperature within
the range of from about 2 to about 10C. and for a crystallization
time of from about 24 hours to about 120 hours. me preferred
temperature is 4C. Preferably, the crystallization time will be
in the range of from about 72 to about 120 hours, with the most
preferred crystallization time being 72 hours.
Most of the supernatant is decanted from the resulting
glucagon crystals, usually through a filter. The
,
:
'., ,': .
-13-
,",_~
~, .. . .. . . . . .

1~3'.L~`7~
remaining supernata~-t is removed from the glucagon crystals,
usually by centrifugation. The purified glucagon then is
washed successively with dilute saline (usually 0.001
percent) and water. The glucagon then is lyophilized and
stored in the cold.
Depending upon the purity of the glucagon obtained
from the second step and the purity desired in the final
purified glucagon, one or more additional crystallizations may
be employed. It has been found, however, that a total of two
crystallizations usually is sufficient to yield glucagon
having a purity of at least 80 percent, based on biological
assay in cats.
; When two crystallizations are employed, the fol-
lowing procedure is preferred: The first crystallization is
carried out as described hereinabove and the crystals are dis-
solved in an alkaline solution. The second crystallization
employs acidification to a pH of from about 7.0 to about 8.5,
pre~erably from about 7.3 to about 7.5, and most preferably
; about 7.4. Dissolution and the filtration procedure, if em-
ployed, preferably are carried out at a temperature of from
about 35 to about 45~C., most preferably at a temperature of
about 40C. The glucagon concentration preferably is about
. ,. ~ ..
lO mg~/ml~ -
If desired, the supernatants from any one or all of
the crystallization procedures can be recycled. For example,
~ll dissolved protein contained in any supernatant can be
precipitated by adjusting the pH with dilute hydrochloric
acid to 2.5 - 3.0 and adding 20 percent of sodium chloride,
~` weight per volume. The precipitate thus obtained can besubjected to the first step of the process of the present
X-3572 -14-
~,
.... :~ , - , .
. . .

:~v~ r~ ~
invention either separately or dissolved in alkaline
crystallization supernatant.
As discussed hereinbefore, the alkaline crystal-
lization supernatant normally contains dissolved therein
substantially more insulin than glucagon. This insulin is
a component of the glucagon-containing protein obtained by
isoelectric precipitation. While the second step in the
process i.e., separation of glucagon from other proteins,
effectively separates glucagon from insulin, the separa-
tion procedure can be detrimental to the insulin component of
the protein mixture. Consequently, it often is desirable to
carry out the first step of the process by means of a pro-
cedure, such as ion-exhange chromatography, which also will -
result in the separation of insulin from glucagon.
It should be pointed out, however, that ion-exchange
chromatography is not the only means of separating insulin
from glucagon prior to separating glucagon from other proteins.
For example, the precipitate from an isoelectric precipitation
can be subjected to what is referred to in the art as a hyper-
glycemic factor fractionation. Briefly, such a procedure in-
volves salting out glucagon from a slightly alkaline, phenolic ~ `
aqueous medium. Hyperglycemic factor fractionation has been
described by Staub, et al, supra. The insulin-containlng
supernatant is recycled in the insulin process, while the pre-
cipitated crude glucagon is employed in step two of the present
process.
While not essential to the process of the present
invention, it is preferred that the supernatant from the
fibril-formation step be recycled in the insulin process,
usually at the beginning of the alkaline crystallization ;
X-3572 -15-
:. . : , - -,: -

step disclosed in said U.S. Patent 3,719,655. Of course, such
recycling is not necessary if insulin has been separated
from glucagon, as described hereinbefore, prior to
fibril formation. In such an instance, however, the
insulin thus separated would be recycled in the insulin
process.
The present process and its relationship to the
insulin process perhaps is better understood by referring
to the drawing which illustrates as a flow diagram one em-
bodiment of the present invention. For the sake of simplicity,the supernatants obtained after the first and third steps of -
the present process are shown as being discarded, it being ~-
understood that such supernatants can be recycled as described
hereinbefore.
The alkaline crystallization procedure of U.S. Patent
3,719,655 is shown at the top of the drawing. The alkaline
crystallization procedure gives alkali metal or ammonium
insulin and a supernatant, as shown. Because the alkaline -
crystallization procedure and the al~ali metal or ammonium
insulin obtained therefrom are a part of the insulin
process, the blocks representing both the procedure and
the insulin are enclosed by a broken line and labeled
"Insulin Process." Evexything without said broXen line,
therefore~ is a part of the present process and is labeled
"Glucagon Process."
The process begins, as shown, with the alkaline
crystallization supernatant. The preferred steps comprising
the present process then are carried out, giving the iso-
electric precipitate, glucagon fibrils, and crystallized glu-
cagon, respectively, as shown. The drawing also indicates
X-3572 -16-
' '` ' . .
' ~' " ~ ,
.~ .

'7~75 :'
return of the supernatant from the fibril formation step to
the insulin process.
Unless otherwlse stated, all temperatures are in
degrees centigrade.
Example 1
Alkaline crystallization supernatant, 14.75 liters,
from the processing of 13,000 lbs. of beef/pork pancreas, -
having a solids content of 40.7 mg./ml., was diluted with
1.45 liters of absolute ethanol. The pH of the resulting ~
solution was adjusted to 5.2 with 3 N hydrochloric acid. ~ -
~ . .
The solution was chilled at 5 overnight. The precipitate
which had formed was collected by filtration, dissolved in
11.28 liters of 0.01 N hydrochloric acid containing 0.2
percent phenol, weight per volume, (referred to hereinafter
as acid-phenol water) and the resulting solution assayed:
Total solids: 512.6 g. (45.4 mg./ml.)
Insulin: 87.43 Units/ml. (1.93 Units/mg. solids)
Glucagon: 463.7 mcg~/ml. (L.02 percent of total ~`~
., .
solids)
An 870-ml. portion o~ the solution was removed for testing, `
leaving 10.4 li~ers containing about 473 g. of solids.
!
~ To carry out a hyperglycemic factor fractionation~
i the above solution was diluted with 111.8 liters of acid~
~` phenol water, giving a total volume of 122.2 liters with
-', a solids content o~ 0.387 percent. To the diluted solution ;~
were added 245.8 ml. of liqui~ied phenol, 941 g. of sodium
. chloride, and sufficient 40 percent aqueous sodium hydroxide
to adjust the pH to g.~ in order to aid dissolution of all
solids. The pH then was adjusted to 7.5 with 3 N hydro- -
chloric acid. The resulting solution was chilled ~t 5 for
X-3572 -17-
: :
... ...

1-2 days, during which time a precipitate formed. The
supernatant was decanted and filtered under suction. The
precipitate was collected by centrifugation. The solids
obtained by filtration and centrifugation were combined and
dissolved in 10 liters of acid-phenol water; the resulting
solution assayed as follows:
Total solids: 75.0 g. (7.5 mg./ml.)
Insulin: 6.33 Units/ml.
Glucagon: 2-75 mcg./ml. (5.01 percent of total solids)
The solution was diluted to a solids concentration of
5.0 mg./ml. by adding an additional 5 liters of acid-phenol
water. A 5.0-liter portion of the resulting solution was
removed for testing, leaving 10.0 liters of solution contain-
ing about 50 g. of solids.
To the remaining solution were added, with agitation,
8.0 ml. of 0.5 M aqueous ethylenediaminetetraacetic acid
(as the tetrasodium salt) and 60 ml. of 50 percent aqueous
ammonium sulfate. Agitation was continued for 16 hours at
ambient temperature. The glucagon flbrils which had formed
were collected by centrifugation and washed twice with acid-
phenol water which contained ethylenediaminetetraacetic acid
and ammonium sulfate as before.
The glucagon fibrils were suspended in 10 liters of
water containing 0.2 percent phenol, weight per volume. The -~
mixture was heated to 40 and the pH adjusted to 10.5 by ~ -
addiny 150 ml. of 10 percent aqueous potassium hydroxide. ~ -
The solution then was heated to 60 while the pH was adjusted
to 7.8 by the addition of 68 ml. of 10 percent phosphoric acid.
After the solution temperature- reached 60, the pH was
further adjusted to 5.0 by adding an additional 68 ml. of 10
X-3572
.,
.. . .
. , , . ~, . ~ ~

~v~ 7~
percent phosphoric acid. The solution then was gravity
filtered while ho-t and the filtrate was chilled, with agitation, ~-
at 5 for 72 hour~. The glucagon which had precipitated `
was isolated by filtration. The solid thus obtained was
dissolved as described above for the glucagon fibrils; how-
ever, upon adjusting the pH to 10.5 the total volume was 870
. . .
ml. The solution then was heated to 60, the pH was adjusted
to 5.0 with 10 percent phosphoric acid, and the resulting
solution was gravity filtered while hot. The filtrate was
cooled and agitated as before. The precipitated glucagon
was collect~d by centrifugation and then lyophilized, giving
.:
1.84 g. of purified glucagon. This corresponds to 74 -
percen~ of the glucagon available prior to fibril formation,
and to 39 percent of the glucagon available after precipitation
of protein from the alkaline crystalli~ation supernatant
tallowance being made for sample removals)
Example 2
.
~ The alkaline crystallization mother liquors from ~ ~
. .
- three crystallizations of insulin derived from 65,257 lbs.,
~20 82,006 lbs., and 108,397 lbs. of a 2:1 mixture of beef/pork
~pancreas were separated from the insulin crystals by
centxifugation. The respective mother liquors measured
-~ ~60 liters, 515 liters, and 680 liters, to which were added
.
; Sl liters, 57.2 liters, and 75.5 liters of absolute alcohol, ~;~
respectively, and each was adjusted to pH 5.0 with 3N
HCl, agitated 15 minutes, and chilled for at least 24 hours.
'I .
~`
3 Assays of the mother liquors before precipitation and the
r~ 501uti~ns Qf the precipitates were tl) 1150 mcg. glucagon
. , . : - :
and 228 U~its insulin/lb. original pancreas (O.P.) in moth~r
liquor; 839 mcg. glucagon and 291 Units/lb. O.P, 59.7 mg.
~-3572 ~ 19-
, ~ . . . .
" ~ ... .
, . .

~Lt~)4~!7 7~
solids/lb. O.P. in solution of the precipitate, 158 liters;
(2) 736 mcg. glucagon and 139 U insulin/lb. O.P. in mother
liquor; 345 mcg. glucagon and 123 U insulin/lb. O.P. and 27.8
mg. solids/lb. O.P. in solution of the precipitate, 150 liters.
(3) 1214 mcg. glucagon and 218 U. insulin/lb. O.P. in mother
liquor; 946 mcg. and 191 U insulin/lb. O.P. and 59.0 mg.
solids/lb. O.P. in solution of precipitate, 156 liters. The
precipitates were collected by filtration and dissolved in
acid-phenol water (prepared as described in Example 1).
The solutions of the pH 5.0 precipitates were
combined to give 464 liters (12,570 gm. solids), and diluted to
630 liters with acid-phenol water to make the solution 2.0
percent solids, and adjusted to pH 2.1 with additional
3N HCl. The solution was treated with 0.3 percent ammonium
sulfate, which was added as a 50 percent solution ~6 ml/l,
3,780 ml), and stirred slowly 24 hours at 25C. during
fibril formation, then allowed to stand 48 hours at 15C.
The glucagon fibrils were separated from the remaining
solution by centrifugation. The supernatant solution was
assayed (contained 222 mcg. glucagon and 114 U insulin/lb.
O.P.) and returned for insulin processing. The glucagon
fibrils were suspended in 450 liters of cold water containing
0.2 p~rcent phenol, 2,700 ml. of 50 percent ammonium
sulfate solution was added, and the mixture was stirred slowly
for 30 minutes to wash the fibrils; the fibrils were again --
collected by centrifugation and the wash discarded. The
glucagon fibrils were suspended in 275 liters of water contain- ;
ing 0.2 per~ent phenol and adjusted to pH 3.85 using 10
percent phosphorlc acid, and assayed: Solids, 5.48 mg./lb.
O.P. (0.52 percent; 1,404 g. from 255,660 lbs. O.P.); ~ -
X-3572 -20-
. - :- . . -
: . . . . .

glucagon, 212 mcg./l~. O.P. (54.2 g.).
The glucagon fibril suspension, 275 liters, was
divided into two portions of (l) 135 liters and (2) 140
liters, respectively~ for the first crystallization. The
first portion was diluted to 140 liters with 0.2 percent
phenol-water to make a 0.5 percent solids concentration;
the other portion was left at 0.52 percent solids. Each
fibril suspension was warmed to 60~C. and adjusted to
pH 9.0-ll.0 l(l) 9.9, (2) 9.7] with lO percent potassium
hydroxide to obtain a clear solution; 281 g. of "Norite Al'* (0.4
g/g solids) was added, and after 10 minutes agitation the solu-
tion was readjusted to pH 5.0 using lO percent phosphoric acid,
and filtered while hot on funnels with ED No. 613 filter
paper. The filtrate tcrystallization solution) was further
agitated slowly for 16-20 hours while chilling at 4C. to
promote uniform glucagon crystallization. The precipitate
separated by filtration at pH 5.0, 60C., was reprocessed
for additional glucagon crystals by suspending in 120 liters
of 0.2 percent phenol-water at 0.5 percent solids concentration
(solids assay, 8.0 g.), warming to 60~C., adjusting to pH
lO.0 to dissolve the solids, agitating lO minutes, and
readjusting the pH to S.0 with lO percent phosphoric acid
and filtering while hot using gravity filtration. The
filtrate was agitated slowly for 16-20 hours while chilling
to 4C. Crystallization usually is complete after 72-120
hours. The second pH 5.0 precipitate was discarded. The
~; bulk of the crystallization mother liquors from the 1st and
2nd crystallization mixtures was decanted and filtered by
` .
suction. The 1st mother liquor was treated with 20 percent
(w/v3 sodium chloride in each case to precipitate any glucagon
X 3572 *Trademark for purified activated charcoal of vegetable origin,
used as a decolorizing agent.
.
-21-
.: ,~ . -
', ~
: - ,.

~3Lq ~r,J~,
that failed to crystallize. These precipitates were pooled
with other lots and reprocessed after reprecipikating at pH 4.6
through another crystallization to provide an additional
yield of glucagon crystals. The glucagon crystals from the
two portions providing the first crop and the crystals
obtained from reworking the combined pH 5.0 precipitates
from the first crystallizations that gave the second crop, ~ -
were collected by centrifugation for 3 minutes, separated
from the mother liquors, transferred to lyophilization con-
tainers using cold water as the suspending medium, and
freeze-dried. The glucagon crystals from the intermediate
crystallization were weighed and samples assayed. Glucagon
intermediate crystals: yields, (lst crop) (1) 41.0 g. (91.7
percent pure) and (2) 44.0 g. (86.8 percent pure) for 85.0 g.
(89.1 percent pure), 75.8 g. glucagon, 292 mcg./lb. O.P. (pure~
or 332 mcg./lb~ (as is); first rework crystals (2nd crop),
yield, l9.0 g. (100.0 percent pure), 75 mcg./lb. O.P. (pure
and as is); second reqork crystals (lst mother liquors),
yield, 22.0 g. (46.0 percent pure) or 9.9 g., 39 mcg./lb. O.P.
(pure) or 85 mcg./lb. (as is). Total yield: 126.0 g.
solids (476 mcg./lb. O.P.) of 83.1 percent purity, or 104.7
g. glucagon (409 mcg./lb. O.P.).
Recrystallization was performed in conjunction with ~ ;
other intermediate crystals accumulated. The final glucagon
crystals represented 85 percent of the glucagon weight
present in the intermediate crystals. Recrystallization was
done at pH 7.5 after dissolving the intermediate crystals at
} p~ 8.0 - 10.0 with lO percent potassium hydroxide, 40C~
at l.0 percent solids, and readjusting to pH 7.5 with lO
percent phosphoric acid, filtering, and chilling. The final
X-3S72 -22-
" :
, . . . . . .
".
.,: ,...... . '' -' : .

-~ :
crystals were collected by centrifugation after decanting
the bulk of the mother liquor (which was reprocessed for~
some additional yield), washed with 0.001 percent sodium
chloride solution twice, cold distilled water once, and
freeze-dried. The calculated yield was 89.0 g. or 348
mcg./lb. O.P. and the recovery from the aIkaline crystal~
lization mother liquor 33.2 percent.
~ .
X-3572 -23- ~
~ ' " ~

Representative Drawing

Sorry, the representative drawing for patent document number 1043775 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: Expired (old Act Patent) latest possible expiry date 1995-12-05
Grant by Issuance 1978-12-05

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
ELI LILLY AND COMPANY
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column (Temporarily unavailable). To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Cover Page 1994-05-23 1 19
Claims 1994-05-23 3 96
Abstract 1994-05-23 1 14
Drawings 1994-05-23 1 17
Descriptions 1994-05-23 22 914